330 related articles for article (PubMed ID: 34685540)
1. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy.
García-Merino A
Cells; 2021 Sep; 10(10):. PubMed ID: 34685540
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
[TBL] [Abstract][Full Text] [Related]
3. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
Carnero Contentti E; Correale J
Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
Saberi D; Geladaris A; Dybowski S; Weber MS
Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515
[TBL] [Abstract][Full Text] [Related]
5. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
6. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
8. Navigating a paradigm shift: Bruton's tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy.
Rao AG
Int Immunopharmacol; 2024 Jun; 135():112265. PubMed ID: 38781611
[No Abstract] [Full Text] [Related]
9. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
[TBL] [Abstract][Full Text] [Related]
10. BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy.
Li R; Tang H; Burns JC; Hopkins BT; Le Coz C; Zhang B; de Barcelos IP; Romberg N; Goldstein AC; Banwell BL; Luning Prak ET; Mingueneau M; Bar-Or A
Acta Neuropathol; 2022 Apr; 143(4):505-521. PubMed ID: 35303161
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis.
Carnero Contentti E; Correale J
Expert Opin Emerg Drugs; 2020 Dec; 25(4):377-381. PubMed ID: 32910702
[No Abstract] [Full Text] [Related]
12. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
Geladaris A; Torke S; Weber MS
CNS Drugs; 2022 Oct; 36(10):1019-1030. PubMed ID: 36178589
[TBL] [Abstract][Full Text] [Related]
13. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Liu J; Chen C; Wang D; Zhang J; Zhang T
Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
[TBL] [Abstract][Full Text] [Related]
14. Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier.
Greenberg BM
Neurol Clin; 2024 Feb; 42(1):155-163. PubMed ID: 37980113
[TBL] [Abstract][Full Text] [Related]
15. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
Lin P; Zhang D; Lin J
Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
Keaney J; Gasser J; Gillet G; Scholz D; Kadiu I
J Neuroimmune Pharmacol; 2019 Sep; 14(3):448-461. PubMed ID: 30758770
[TBL] [Abstract][Full Text] [Related]
18. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Whang JA; Chang BY
Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
[TBL] [Abstract][Full Text] [Related]
20. Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis.
Shulga O; Chabanova A; Kotsiuba O
Postep Psychiatr Neurol; 2023 Mar; 32(1):23-30. PubMed ID: 37287740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
